JP
ALXN

John Paulson’s Alexion Pharmaceuticals ALXN Stock Holding History

John Paulson’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200,000
Closed -$24.3M – 99
2017
Q2 		$24.3M Hold
200,000
– – 0.33% 40
2017
Q1 		$24.2M Hold
200,000
– – 0.32% 41
2016
Q4 		$24.5M Buy
+200,000
New +$24.5M 0.31% 44

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

John Paulson's ALXN Position: Q2 2021 in Review

John Paulson sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 1,400,000 shares — an estimated $214M sold.

John Paulson first reported a position in ALXN in Q1 2016 and held it in 8 quarters. The position peaked at $214M in Q1 2021. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • John Paulson reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • John Paulson sold 1,400,000 Alexion Pharmaceuticals shares in Q2 2021, an estimated $214M.
  • John Paulson first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 8 quarters.
  • John Paulson's Alexion Pharmaceuticals position peaked at $214M in Q1 2021.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Paulson & Co's 13F filing for Q2 2021, filed 16 Aug 2021.